REGN - CIK 0000872589
REGENERON PHARMACEUTICALS, INC. trades as REGN and has a market capitalization of $56.80 B, making it the #292 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $14.34B, up 1.0% from the prior year and net income of $4.50B. This page tracks REGENERON PHARMACEUTICALS, INC. through 985 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years REGENERON PHARMACEUTICALS, INC.'s revenue grew from $4.86B to $14.34B, a compound annual growth rate of 12.8%. Net profit margin expanded from 18.4% to 31.4% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Institutional holdings | 13F-HR | 2026-05-08 |
| Insider trade | 4 | 2026-05-04 |
| SCHEDULE 13G | - | 2026-04-30 |
| Quarterly report | 10-Q | 2026-04-29 |
| Major company event | 8-K | 2026-04-29 |
| Proxy materials | DEFA14A | 2026-04-24 |
| Proxy statement | DEF 14A | 2026-04-24 |
| Annual report to shareholders | ARS | 2026-04-24 |
Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak | Regeneron Pharmaceuticals Inc.
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss | Regeneron Pharmaceuticals Inc.
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis | Regeneron Pharmaceuticals Inc.
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas | Regeneron Pharmaceuticals Inc.
The largest companies sharing REGENERON PHARMACEUTICALS, INC.'s SEC industry classification (pharmaceutical preparations).
REGENERON PHARMACEUTICALS, INC. (REGN) has a market capitalization of $56.80 B as of 2026-06-10, ranking #292 among US-listed companies.
REGENERON PHARMACEUTICALS, INC. reported revenue of $14.34B for fiscal year 2025, an increase of 1.0% year over year.
Yes. REGENERON PHARMACEUTICALS, INC. reported net income of $4.50B in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma | Regeneron Pharmaceuticals Inc.